Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP31: Development and validation of the IBD-REFER criteria: when should a general practitioner or paediatrician refer a patient for suspected IBD?

ECCO '19 Copenhagen

Year: 2019
Authors:

O. Atia1, G. Focht1, A. Assa2, B. Yerushalmi3, R. Shaoul4, D. S. Shouval5, A. Bar-Gil Shitrit6, B. Koslowsky6, I. Dotan7, R. Kariv8, E. Lavon8, D. Turner*1

1Institute of Pediatric Gastroenterology, The Hebrew University of Jerusalem, Jerusalem, Israel, 2Schneider Children’s Hospital, Petach Tikva, Israel, 3Soroka University Medical Center and Faculty of Pediatric Gastroenetrology Unit, Health Sciences, Beer-Sheva, Israel, 4Pediatric Gastroenterology Institute, Ruth Children’s Hospital, Rambam Medical Center, Haifa, Israel, 5Pediatric Gastroenterology Unit, Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Ramat gan, Israel, 6Digestive diseases institute, Shaare Zedek Medical Center, Jerusalem, Israel, 7Division of Gastroenterology, Rabin Medical Center, Sackler Faculty of Medicine, Petach Tikva, Israel, 8Health Division, Maccabi Healthcare Services, Jerusalem, Israel

DOP32: Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Hisamatsu*1, S. Kato2, R. Kunisaki3, M. Matsuura4, M. Nagahori5, S. Motoya6, M. Esaki7, N. Fukata8, S. Inoue9, T. Sugaya10, H. Sakuraba11, F. Hirai12, K. Watanabe13,14, T. Kanai15, M. Naganuma15, H. Nakase16, Y. Suzuki17, M. Watanabe5, T. Hibi18, M. Nojima19, T. Matsumoto20, DIAMOND2 Study Group1

1Kyorin University School of Medicine, The Third Department of Internal Medicine, Tokyo, Japan, 2Saitama Medical Centre, Saitama Medical University, Department of Gastroenterology and Hepatology, Saitama, Japan, 3Yokohama City University Medical Center, Inflammatory Bowel Disease Centre, Kanagawa, Japan, 4Graduate School of Medicine, Kyoto University, Department of Gastroenterology and Hepatology, Kyoto, Japan, 5Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, 6Sapporo Kosei General Hospital, Inflammatory Bowel Disease Center, Sapporo, Japan, 7Graduate School of Medical Sciences, Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan, 8Kansai Medical University, Third Department of Internal Medicine, Osaka, Japan, 9Kobe City Medical Center General Hospital, Departments of Gastroenterology, Hyogo, Japan, 10Japan Red Cross Ashikaga Hospital, Department of Internal Medicine, Tochigi, Japan, Japan, 11Hirosaki University Graduate School of Medicine, Department of Gastroenterology and Hematology, Hirosaki, Japan, 12Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan, 13Osaka City General Hospital, Division of Gastroenterology, Osaka, Japan, 14Hyogo College of Medicine, Department of Intestinal Inflammation Research, Nishinomiya, Japan, 15Keio University, Department of Internal Medicine, School of Medicine, Tokyo, Japan, 16Sapporo Medical University School of Medicine, Department of Gastroenterology and Hepatology, Sapporo, Japan, 17Toho University Sakura Medical Center, Department of Internal Medicine, Sakura, Japan, 18Kitasato University, Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan, 19Institute of Medical Science Hospital, University of Tokyo, Center for Translational Research, Tokyo, Japan, 20Iwate Medical University, Division of Gastroenterology, Department of Medicine, Morioka, Japan

DOP33: Long-term clinical efficacy of ustekinumab in refractory Crohn’s disease : a multi-centre Belgian cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Liefferinckx*1, B. Verstockt2, A. Gils3, M. Noman2, C. Van Kemseke4, E. Macken5, M. De Vos6, W. Van Moerkercke7, J-F. Rahier8, P. Bossuyt9, J. Dutré10, E. Humblet11, D. Staessen12, H. Peters13, P. Van Hootegem14, E. Louis4, D. Franchimont1, F. Baert15, S. Vermeire2

1Hopital Erasme – ULB, Department of Gastroenterology, Brussels, Belgium, 2University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 3KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 4Centre Hospitalier Universitaire Sart-Tilman – ULG, Department of Gastroenterology, Liège, Belgium, 5Universiteit ziekenhuis Antwerpen – UZA, Department of Gastroenterology, Antwerpen, Belgium, 6Universitair ziekenhuis Gent, Department of Gastroenterology, Gent, Belgium, 7AZ Groeninge, Department of Gastroenterology, Kortrijk, Belgium, 8Centre Hospitalier Universitaire Mont-Godinne – UCL, Department of Gastroenterology, Yvoir, Belgium, 9Imeldaziekenhuis, Department of Gastroenterology, Bonheiden, Belgium, 10Ziekenhuis Netwerk Antwerpen, Department of Gastroenterology, Antwerpen, Belgium, 11Ziekenhuis Oost-Limburg – Campus Sint-Jan, Department of Gastroenterology, Genk, Belgium, 12GZA Sint-Vincentius ziekenhuis, Department of Gastroenterology, Antwerpen, Belgium, 13Algemeen Ziekenhuis Sint-Lucas, Department of Gastroenterology, Gent, Belgium, 14Algemeen Ziekenhuis Sint-Lucas, Department of Gastroenterology, Brugge, Belgium, 15AZ Delta, Department of Gastroenterology, Roeselare-Menen, Belgium

DOP34: Disease activity patterns during the first 5 years after diagnosis in children with ulcerative colitis: a population-based study

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Aloi*1, M. Bramuzzo2, L. Norsa3, S. Arrigo4, M. Distante5, E. Miele6, A. Agrusti2, C. Romano7, C. Giobbi5, R. Panceri8, L. D’Antiga3, S. Cucchiara5, P. Alvisi9, SIGENP IBD Working Group1

1Sapienza University of Rome, Department of Pediatrics, Pediatric Gastroenterology Unit, Rome, Italy, 2Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy, 3Ospedale Papa Giovanni XXIII, Pediatric Gastroenterology Hepatology and Nutrition, Bergamo, Italy, 4Istituto Giannina Gaslini, Department of Gastroenterology and Endoscopy, Genoa, Italy, 5Sapienza University of Rome, Department of Pediatric Gastroenterology, Rome, Italy, 6University of Naples ‘Federico II’, Department of Translational Medical Science, Section of Pediatrics, Naples, Italy, 7University of Messina, Department of Pediatric Gastroenterology and Endoscopy, Messina, Italy, 8San Gerardo Hospital, Monza, Italy, 9Maggiore Hospital, Bologna, Italy

DOP35: Innate immune dysregulation, detectable up to 6 years before the diagnosis of Crohn’s disease, is significantly amplified in patients with a complicated phenotype

ECCO '19 Copenhagen

Year: 2019
Authors:

R. S. Choung*1, F. Petralia2, J. Torres3,4, T. Sato5, X-j. Li6, P. Wang2, S. Telesco5, C. Porter7, R. Laird7, R. Gutierrez7, F. Princen6, S. Plevy5, R. Strauss5, M. Riddle7, J. Murray1, J. F. Colombel3, PREDICTS (PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects) Study Group1

1Mayo Clinic, Gastroenterology and Hepatology, Rochester, USA, 2Icahn School of Medicine, Genetics and Genomic Sciences, New York, USA, 3Icahn School of Medicine at Mount Sinai, New York, USA, 4Hospital Beatriz Ângelo, Lisbon, Portugal, 5Janssen R&D, Spring House, USA, 6Prometheus Laboratories Inc., San Diego, USA, 7Naval Medical Research Center, Silver Spring, USA

DOP36: Gut microbial variations in patients with quiescent Crohn’s disease predict subsequent disease flare

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Braun1, A. Di Segni1, M. BenShoshan1, S. Neuman1, O. Picard1, K. Sosnovski1, G. Efroni1, B. Weiss1, D. Yablecovitch1, A. Lahat1, R. Eliakim1, U. Kopylov1, S. Ben-Horin1, Y. Haberman*1,2, Israeli IBD Research Nucleus (IIRN)1

1Sheba Medical Center, Tel Hashomer, Israel, 2Cincinnati Children Hospital Medical Center, Cincinnati, USA

DOP37: Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: a large single-centre experience

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Verstockt*1,2, E. Mertens1, A. Outtier1, G. Van Assche1,2, S. Vermeire1,2, M. Ferrante1,2

1University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 2KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium

DOP38: A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Verstockt*1,2, S. Verstockt3, P. Sudahakar2,4,5, J. Dehairs6, H. Blevi2, G. Van Assche1,2, S. Vermeire1,2, M. Ferrante1,2

1Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, 2KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 3KU Leuven, Department of Human genetics, Laboratory for Complex Genetics, Leuven, Belgium, 4Earlham Institute, Norwich, UK, 5Quadram Institute, Norwich, Belgium, 6Department of Oncology, Laboratory of Lipid Metabolism and Cancer, Leuven, Belgium

DOP39: Safety of combination biologic and anti-rejection therapy post-liver transplantation in patients with inflammatory bowel disease: London Ontario experience

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Al Draiweesh*1,2, C. Ma1,3, M. Alkhattabi1, N. Chande1, B. G. Feagan1, J. C. Gregor1, R. Khanna1, P. Marotta1, A. Sandhu1, K. Qumosani1, A. Teriaky1, M. Brahmania1, V. Jairath1,4,5

1Western University, Department of Medicine, Division of Gastroenterology, London, Ontario, Canada, 2King Fahad Specialist Hospital, Department of Medicine, Division of Gastroenterology, Dammam, Saudi Arabia, 3University of Calgary, Division of Gastroenterology and Hepatology, Calgary, Alberta, Canada, 4King Abdulaziz University, Department of Medicine, Rabigh, Saudi Arabia, 5Western University, Department of Epidemiology and Biostatistics, London, Ontario, Canada

DOP40: Effectiveness and safety of reference infliximab and biosimilar in Crohn’s disease: a French equivalence study

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Meyer*1, J. Rudant2, J. Drouin2, A. Weill2, F. Carbonnel3, J. Coste2

1Caisse Nationale Assurance Maladie, Paris, France, 2Caisse Nationale de l’Assurance Maladie, Paris, France, 3Hopital Bicetre, Le Kremlin Bicetre, France

DOP41: Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Chiorean1, C. Su2, K. Matsuoka3, A. Orlando4, A. J. Thorpe2, C. I. Nduaka2, D. S. Chapman5, D. A. Woodworth2, N. Lawendy2, G. S. Friedman2, R. D. Cohen*6

1Virginia Mason Medical Center, Seattle, WA, USA, 2Pfizer Inc., Collegeville, PA, USA, 3Toho University Sakura Medical Center, Sakura, Chiba, Japan, 4University of Palermo, IBD Unit, Palermo, Italy, 5Pfizer Inc., New York, NY, USA, 6University of Chicago Medicine, Chicago, IL, USA

DOP42: Dietary therapies induce rapid response and remission in active paediatric Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Sigall Boneh*1,2, J. Van Limbergen3, A. Assa4, R. Shaoul5, E. Wine6, P. Milman7, S. Cohen8, M. Kori9, S. Peleg10, A. On11, H. Shamaly12, L. Abramas1, A. Levine1,2

1Wolfson Medical Center, Pediatric Gastroenterology, Holon, Israel, 2Tel Aviv University, Tel Aviv, Israel, 3Dalhousie University, Halifax, Canada, 4Schneider Hospital, Petach Tikva, Israel, 5Meyer Hospital, Haifa, Israel, 6University of Alberta, Edmonton, Canada, 7Hadassah Hospital, Jerusalem, Israel, 8Tel Aviv Medical Center, Tel Aviv, Israel, 9Kaplan Hospital, Rehovot, Israel, 10HaEmek Hospital, Afula, Israel, 11Poriah hospital, Tiberias, Israel, 12French Hospital, Nazareth, Israel

DOP43: Long-term efficacy of tofacitinib in patients who received extended induction therapy: results of the OCTAVE open study for tofacitinib delayed responders

ECCO '19 Copenhagen

Year: 2019
Authors:

D. T. Rubin1, M. C. Dubinsky2, M. Lukas*3, D. Quirk4, C. I. Nduaka4, E. Maller4, N. Lawendy4, C. Kayhan4, H. Fan4, D. A. Woodworth4, G. Chan4, C. Su4

1University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, USA, 2Icahn School of Medicine at Mount Sinai Hospital, Department of Pediatrics and Medicine, New York, NY, USA, 3Charles University, Prague, Czech Republic, 4Pfizer Inc., Collegeville, PA, USA

DOP44: Efficacy and safety of tacrolimus in ulcerative colitis: a nationwide, multi-centre study from GETECCU

ECCO '19 Copenhagen

Year: 2019
Authors:

I. Rodriguez-Lago*1, J. Castro-Poceiro2, A. Fernández-Clotet2, F. Mesonero3, A. López-Sanromán3, A. López-García4, L. Márquez4, A. Clos-Parals5, F. Cañete5, M. Vicuña6, Ó. Nantes6, O. Merino7, V. Matallana Royo8, J. Gordillo9, A. Elorza1, R. Vicente10, M. J. Casanova11,12, R. Ferreiro-Iglesias13, P. Pérez-Galindo14, J. M. Benítez15,16, C. Taxonera17, M. J. García García18, E. Martín Arranz19, M. Calafat20, A. Martín-Cardona21,22, F. Muñoz Núñez23, J. O. Miquel-Cusachs24, E. Sáinz Arnau25, J. P. Gisbert11, Young IBD Group from GETECCU1

1Hospital de Galdakao, Gastroenterology, Galdakao, Spain, 2Hospital Clinic, Gastroenterology, Barcelona, Spain, 3Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain, 4Hospital del March, Gastroenterology, Barcelona, Spain, 5Hospital Universitario Germans Trias i Pujol, Gastroenterology, Badalona, Spain, 6Complejo Hospitalario de Navarra, Gastroenterology, Pamplona, Spain, 7Hospital de Cruces, Gastroenterology, Bilbao, Spain, 8Hospital Universitario Puerta de Hierro, Gastroenterology, Majadahonda, Spain, 9Hospital de la Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain, 10Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain, 11Hospital Universitario de La Princesa, Gastroenterology, Madrid, Spain, 12Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain, 13Hospital Clínico Universitario de Santiago de Compostela, Gastroenterology, Santiago de Compostela, Spain, 14Hospital Montecelo, Gastroenterology, Pontevedra, Spain, 15Hospital Universitario Reina Sofía, Gastroenterology, Córdoba, Spain, 16IMIBIC, Córdoba, Spain, 17Hospital Clínico San Carlos, Gastroenterology, Madrid, Spain, 18Hospital Marqués de Valdecilla, Gastroenterology, Santander, Spain, 19Hospital Universitario La Paz, Gastroenterology, Madrid, Spain, 20Hospital Son Llàtzer, Gastroenterology, Palma, Spain, 21Hospital Universitari Mutua Terrassa, Gastroenterology, Terrassa, Spain, 22Centro de Investigación biomédica en red de enfermedades hepáticas y digestivas (CIBERehd), Terrassa, Spain, 23Hospital de Salamanca, Gastroenterology, Salamanca, Spain, 24Hospital Universitario de Girona, Gastroenterology, Girona, Spain, 25Hospital Arnau de Vilanova, Gastroenterology, Lérida, Spain

DOP45: Adequate infliximab exposure during the induction phase is associated with early complete fistula response in patients with fistulizing Crohn’s disease: a post-hoc analysis of the ACCENT-2 trial

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Vande Casteele*1,2, K. Papamichael3, J. Jeyarajah2, M. T. Osterman4, A. S. Cheifetz3

1University of California San Diego, Department of Medicine, La Jolla, USA, 2Robarts Clinical Trials, Inc., London, Canada, 3Beth-Israel Deaconess Medical Center, Harvard Medical School, Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Boston, USA, 4University of Pennsylvania, Department of Medicine, Perelman School of Medicine, Philadelphia, USA

DOP46: Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial

ECCO '19 Copenhagen

Year: 2019
Authors:

W. J. Sandborn*1, M. Ferrante2, B. R. Bhandari3, E. Berliba4, T. Hibi5, G. Geert. R. D’Haens6, J. Tuttle7, K. Krueger8, S. Friedrich8, M. Durante8, V. Arora8, B. Feagan9

1University California San Diego, La Jolla, California, USA, 2UZ Leuven, KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 3Delta Research Partners, LLC, Bastrop, LA, USA, 4Nicolae Testemițanu State University of Medicine and Pharmacy, Chisinau, Moldova, Republic of, 5Kitasato Institute Hospital Center for Advanced IBD Research and Treatment, Minato-ku, Tokyo, Japan, 6Amsterdam University Medical Centers, Amsterdam, The Netherlands, 7Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California, USA, 8Eli Lilly and Company, Indianapolis, Indiana, USA, 9Western University, Robarts Clinical Trials Inc., London, Ontario, Canada

DOP47: Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study

ECCO '19 Copenhagen

Year: 2019
Authors:

G. Van Assche*1, S. R. Targan2, T. Baker3, C. D. O’Brien3, H. Zhang3, J. Johanns3, P. Szapary3, C. Marano3, R. W. Leong4,5, D. Rowbotham6,7, T. Hisamatsu8, S. Danese9, B. E. Sands10, L. Peyrin-Biroulet11

1University of Leuven, Leuven, Belgium, 2Cedars-Sinai Medical Center, Los Angeles, USA, 3Janssen Research and Development, Spring House, USA, 4Concord Hospital, Sydney, Australia, 5Macquarie University Hospital, Sydney, Australia, 6Auckland City Hospital, Auckland, New Zealand, 7University of Auckland, Auckland, New Zealand, 8Kyorin University, Tokyo, Japan, 9Humanitas Research Hospital, Milan, Italy, 10Icahn School of Medicine at Mount Sinai, New York, USA, 11Nancy University Hospital, Vandœuvre-lès-Nancy, France

DOP48: Amiselimod, a selective S1P receptor modulator in Crohn’s disease patients: a proof-of-concept study

ECCO '19 Copenhagen

Year: 2019
Authors:

G. D’Haens*1, S. Danese2, M. Davies3, M. Watanabe4, T. Hibi5

1Academic Medical Centre, Amsterdam, The Netherlands, 2Humanitas Research Hospital, Gastroenterology, Milano, Italy, 3Mitsubishi Tanabe Europe Ltd., London, UK, 4Tokyo Medical and Dental University, Gastroenterology, Tokyo, Japan, 5University Kitasato Hospital, Gastroenterology, Tokyo, Japan

DOP49: Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT II

ECCO '19 Copenhagen

Year: 2019
Authors:

W. Reinisch*1, W. J. Sandborn2, S. Danese3, X. Hébuterne4, M. Kłopocka5, D. Tarabar6, T. Vaňásek7, M. Greguš8, P. A. Hellstern9, J. S. Kim10, M. Sparrow11, K. J. Gorelick12, M. Goetsch13, C. Bliss14, C. Gupta15, F. Cataldi14, S. Vermeire16

1Medical University of Vienna, Vienna, Austria, 2University of California San Diego, La Jolla, CA, USA, 3Humanitas University, Milan, Italy, 4University of Nice Sophia Antipolis, Hospital l’Archet, Nice, France, 5Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, 6Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, 7Charles University Hospital, Hradec Králové, Czech Republic, 8Gastroenterology Center, Nitra, Slovakia, 9Nature Coast Clinical Research, Inverness, FL, USA, 10Seoul National University College of Medicine, Seoul, South Korea, 11Alfred Hospital, Melbourne, VIC, Australia, 12Zymo Consulting Group, Newtown Square, PA, USA, 13Shire, Zug, Switzerland, 14Shire, Lexington, MA, USA, 15Cytel Inc., Cambridge, MA, USA, 16University Hospitals Leuven, Leuven, Belgium

DOP50: Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn’s disease: data from the CELEST study

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Peyrin-Biroulet*1, S. Danese2, E. Louis3, P. D. R. Higgins4, M. Dubinsky5, F. Cataldi6, Q. Zhou6, W-J. Lee6, K. Kligys6, A. P. Lacerda6

1University of Lorraine, Nancy, France, 2Istituto Clinico Humanitas, Milan, Italy, 3CHU de Liège et Université de Liège, Liège, Belgium, 4University of Michigan, Ann Arbor, USA, 5Icahn School of Medicine at Mount Sinai, New York, USA, 6AbbVie Inc., North Chicago, USA